Page last updated: 2024-11-11

noroxymorphone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

noroxymorphone: an opioid for spinal analgesia; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5497189
CHEBI ID187724
SCHEMBL ID136548
MeSH IDM0518445

Synonyms (28)

Synonym
morphinan-6-one, 4,5alpha-epoxy-3,14-dihydroxy- (8ci)
morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-, (5alpha)- (9ci)
en 3169
7,8-dihydro-14-hydroxynormorphinone
morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-, (5alpha)-
33522-95-1
14-hydroxydihydronormorphinone
(5alpha)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
(5.alpha.)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
nor oxymorphone
CHEBI:187724
(4r,4as,7ar,12bs)-4a,9-dihydroxy-1,2,3,4,5,6,7a,13-octahydro-4,12-methanobenzouro[3,2-e]isoquinolin-7-one
noroxymorphone
einecs 251-561-5
unii-9nz7111a9o
9nz7111a9o ,
SCHEMBL136548
en-3169
noroxymorphone [usp impurity]
noroxymorphone [who-dd]
naloxone hydrochloride dihydrate impurity a [ep impurity]
(-)-noroxymorphone
morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-, (5.alpha.)-
HLMSIZPQBSYUNL-IPOQPSJVSA-N
4,5alpha-epoxy-3,14-dihydroxy morphinan-6-one
Q25102255
DTXSID80955145
(4R,4AS,7AR,12BS)-4A,9-DIHYDROXY-2,3,4,4A,5,6-HEXAHYDRO-1H-4,12-METHANOBENZOFURO[3,2-E]ISOQUINOLIN-7(7AH)-ONE

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" There were no significant sex-related differences in any of the pharmacokinetic parameters."( Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
Aantaa, R; Kuusniemi, K; Liukas, A; Neuvonen, M; Neuvonen, PJ; Olkkola, KT; Virolainen, P, 2011
)
0.37
"The aim of this study is to evaluate the pharmacokinetic profile of oxycodone and three of its metabolites, noroxycodone, oxymorphone and noroxymorphone after intravenous administration in Chinese patients with pain."( Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain.
Dong, RH; Gao, HZ; Hao, GT; Li, YY; Liang, YG; Liu, ZY; Qu, HY; Wang, XF; Zhang, LJ; Zhou, HY, 2014
)
0.6
"Pharmacokinetic parameters showed that mean values of C(max), AUC(0-t) and AUC(0-∞) of oxycodone were dose dependent, whereas Tmax and t(1/2) were not."( Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain.
Dong, RH; Gao, HZ; Hao, GT; Li, YY; Liang, YG; Liu, ZY; Qu, HY; Wang, XF; Zhang, LJ; Zhou, HY, 2014
)
0.4
" Preterm neonates were found to have the highest pharmacokinetic variability out of the study population."( Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine.
Hautajärvi, H; Heikkinen, M; Hokkanen, J; Kokki, H; Kokki, M; Pitkänen, H; Ranta, VP; Sankilampi, U; Välitalo, P, 2017
)
0.46
"Oxycodone elimination is slower and pharmacokinetic variability more pronounced in neonates when compared to older infants."( Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine.
Hautajärvi, H; Heikkinen, M; Hokkanen, J; Kokki, H; Kokki, M; Pitkänen, H; Ranta, VP; Sankilampi, U; Välitalo, P, 2017
)
0.46
" The pharmacokinetics including the relatively short half-life of oxycodone in patients with ESRD with or without haemodialysis and the absence of unconjugated active metabolites indicate that oxycodone can be used at usual doses in patients requiring dialysis."( Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions.
Amico, P; Dickenmann, M; Duthaler, U; Hammann, F; Haschke, M; Jehle, AW; Kalbermatter, S; Krähenbühl, S; Lenherr, C; Leuppi-Taegtmeyer, A; Liechti, ME; Meyer Zu Schwabedissen, HE; Schmid, Y, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"Haemodialysis performed 6-10 h after dosing removed ∼10% of the administered dose of oxycodone predominantly as unconjugated oxycodone and noroxycodone or conjugated oxymorphone and noroxymorphone."( Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions.
Amico, P; Dickenmann, M; Duthaler, U; Hammann, F; Haschke, M; Jehle, AW; Kalbermatter, S; Krähenbühl, S; Lenherr, C; Leuppi-Taegtmeyer, A; Liechti, ME; Meyer Zu Schwabedissen, HE; Schmid, Y, 2019
)
0.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenanthrenesAny benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (9.09)18.7374
1990's0 (0.00)18.2507
2000's5 (22.73)29.6817
2010's14 (63.64)24.3611
2020's1 (4.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.66 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index53.70 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (4.17%)4.05%
Observational0 (0.00%)0.25%
Other20 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]